About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
Updates on Myeloproliferative Neoplasms Including CML
By
Winship Cancer Institute - Emory University
FEATURING
Anthony Hunter
By
Winship Cancer Institute - Emory University
FEATURING
Anthony Hunter
85 views
May 7, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
08:18
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
Feat.
A. Zhou
Featured Video
16:51
Incyte
Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk
Feat.
C. Harrison
Related Content
AUTOPLAY
ON
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
24:35
Indy Hematology Review
Current Approaches in the Treatment of Myeloproliferative Neoplasms
Feat.
A. Tefferi
08:44
American Contact Dermatitis Society (ACDS)
What to Do When Patch Testing is Negative?
Feat.
M. Montanez-Wiscovich
04:16
Luke Fletcher
Efficacy and Safety of Asciminib in Ph+ CML
09:51
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
Feat.
N. S. Raje
27:37
Indy Hematology Review
Review of Myeloproliferative Neoplasms
Feat.
A. Tefferi
18:04
Ruben Mesa
Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…
24:27
BMFcases
Experts Discuss Pros and Cons of Treatment Approaches in PV
Feat.
T. Bat,
A. Tefferi
07:55
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes …
Feat.
E. Atallah
24:44
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignan…
Feat.
R. Birhiray
23:35
University of Colorado Division of Hematology
2024 Updates in PV/ET
Feat.
B. McMahon
23:15
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
Feat.
M. Levis
05:20
Prithviraj Bose
When to Switch From Hydroxyurea to Ruxolitinib in PV
21:52
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "MF, ET, and PV - Highlights and Clinical Imp…
Feat.
D. Tremblay
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
10:02
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of MPNs - Highlights & Key Take…
Feat.
R. Mesa
16:25
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …
Feat.
N. Cross
31:43
Indy Hematology Review
Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…
Feat.
A. Tefferi
18:42
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
Feat.
A. Goldberg